Trial Profile
Phase II study of continued immunotherapy with FavID (Id-KLH) [mitumprotimut T] and GM-CSF [granulocyte-macrophage colony-stimulating factors] in patients with stable or responding grade 1 or 2 follicular B-cell lymphomas following initial FavID/GM-CSF treatment
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Jan 2006
Price :
$35
*
At a glance
- Drugs Mitumprotimut T (Primary)
- Indications Follicular lymphoma
- Focus Therapeutic Use
- 24 Jan 2006 New trial record.